3,4-dihydro-6-hydroxy-5-(2-propenyl)-1(2H)-naphthalenone | 150599-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3,4-dihydro-6-hydroxy-5-(2-propenyl)-1(2H)-naphthalenone
• 英文别名: 5-allyl-6-hydroxy-tetral-1-one；6-hydroxy-5-prop-2-enyl-2,3,4-trihydro-naphthalen-1-one；6-Hydroxy-5-prop-2-enyl-2,3,4-trihydronaphthalen-1-one；5-allyl-6-hydroxy-3,4-dihydronaphthalen-1(2H)-one；6-hydroxy-5-prop-2-enyl-3,4-dihydro-2H-naphthalen-1-one
• CAS: 150599-40-9
• 化学式: C₁₃H₁₄O₂
• 分子量: 202.253
• InChiKey: JIKYHZQYNBIDHI-UHFFFAOYSA-N

物化性质

• 沸点：
  385.0±41.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-6-hydroxy-5-(2-propenyl)-1(2H)-naphthalenone 在 (tris(triphenylphosphine)rhodium) chloride 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 以47%的产率得到6-hydroxy-5-propyl-1,2,3,4-tetrahydronaphthalene-1-one
  参考文献：
  名称：

  5- substituted tetralones as inhibitors of ras farnesyl trransferase

  摘要：

  本发明提供了式(I)、(II)、(III)和(IV)的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体而言，本发明涉及抑制法尼基转移酶酶的化合物。

  公开号：

  US20040044057A1
• 作为产物：
  描述：

  6-羟基-1-四氢萘酮 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 3,4-dihydro-6-hydroxy-5-(2-propenyl)-1(2H)-naphthalenone
  参考文献：
  名称：

  Predicting the Claisen rearrangement regioselectivity of allylindanyl and allyltetrahydronaphthalenyl ether derivatives by1H NMR experiments

  摘要：

  The regioselectivity of the Claisen rearrangement of allylindanyl and allyltetrahydronaphthalenyl ether derivatives can be predicted by conformational preference detected by H-1 NMR NOE difference spectra and T-1 measurements. Copyright (C) 2000 John Wiley & Sons, Ltd.

  DOI：

  10.1002/1097-458x(200011)38:11<970::aid-mrc756>3.0.co;2-x

文献信息

• Indole derivative having piperidine ring
  申请人：Suzuki Yuichi

  公开号：US20050256103A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

  本发明涉及以下公式所代表的化合物，其药学上可接受的盐，或其作为药物的用途： 其中R1和R2是相邻的取代基，与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物，该基可能被1至4个取代基所取代，所述取代基选自（1）氧代基，（2）羟基等；R3代表氢原子或类似物；R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状，特别是涉及尿液储存的症状的药剂，该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
• Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
  申请人：——

  公开号：US20030003049A1

  公开（公告）日：2003-01-02

  The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.

  本发明提供了包括放射标记的LTB4结合剂和放射标记的灌注成像剂的新型诊断组合物，包括这种组合物的诊断试剂盒，以及在哺乳动物中进行同时成像的方法，包括给予放射标记的LTB4结合剂和放射标记的灌注成像剂，并同时检测结合在LTB4受体上的放射标记的LTB4结合剂和放射标记的灌注成像剂。
• Radiopharmaceuticals for imaging infection and inflammation
  申请人：——

  公开号：US20030124053A1

  公开（公告）日：2003-07-03

  The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备这些放射性药物的试剂和工具包，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位聚集的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1293214A3

  公开（公告）日：2003-03-26

  The present invention provides novel radiopharmaceutials useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备放射性药物的试剂和试剂盒，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位积聚的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• Carboxylic acid Leukotriene B4 antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US05457124A1

  公开（公告）日：1995-10-10

  The invention relates to compounds selected from the group consisting of the formulas: ##STR1## wherein R.sup.2 and Ph are as described herein. These compounds are potent leukotriene B.sub.4 antagonists and are therefore useful in the treatment of inflammatory diseases.

  这项发明涉及从以下公式组成的化合物中选择的化合物：##STR1## 其中R.sup.2和Ph如本文所述。 这些化合物是强效的白三烯B.sub.4拮抗剂，因此在治疗炎症性疾病方面非常有用。